A pill to stop red blood cells from sickling in sickle cell disease
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy
A new oral medicine aims to keep red blood cells from sickling for people with sickle cell disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Illexcor Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11163531 on NIH RePORTER |
What this research studies
This project develops an oral drug based on natural aromatic aldehydes that works two ways to prevent hemoglobin S from forming harmful polymers: one oxygen‑dependent and a novel oxygen‑independent mechanism. Researchers screened hundreds of related compounds and identified a lead molecule with improved anti‑sickling activity and better drug properties. The work focuses on optimizing the compound and completing the lab and animal studies needed to advance toward human testing. If successful, the drug would be positioned as a next‑generation oral treatment to reduce sickling and its complications.
Who could benefit from this research
Good fit: People with sickle cell disease, especially those who continue to have anemia or painful vaso‑occlusive crises despite current treatments, would be the intended candidates.
Not a fit: People without sickle cell disease or those already cured by bone marrow transplant are unlikely to benefit, and some patients with specific allergies or medication interactions may be excluded.
Why it matters
Potential benefit: Could provide a more effective oral therapy that lowers red blood cell sickling and potentially reduces painful crises and organ damage in people with sickle cell disease.
How similar studies have performed: Related aromatic aldehyde drugs (for example, the FDA‑approved Voxelotor) showed the approach can work but had limits in reducing vaso‑occlusive events, and this project builds on that with a novel oxygen‑independent mechanism.
Where this research is happening
Richmond, United States
- Illexcor Therapeutics, LLC — Richmond, United States (Active)
Researchers
- Principal investigator: Light, David Richard — Illexcor Therapeutics, LLC
- Study coordinator: Light, David Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.